Abbott Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Core Insights - Abbott Laboratories is set to release its second-quarter earnings results on July 17, with expected earnings of $1.25 per share, an increase from $1.14 per share in the same period last year [1] - The company anticipates quarterly revenue of $11.02 billion, up from $10.38 billion a year earlier [1] - Abbott received FDA approval for its Tendyne™ transcatheter mitral valve replacement system, which positively impacted its stock price [2] Analyst Ratings - Morgan Stanley analyst David Lewis maintained an Equal-Weight rating and raised the price target from $127 to $137 [5] - Raymond James analyst Jayson Bedford maintained an Outperform rating and increased the price target from $132 to $142 [5] - Barclays analyst Matt Miksic maintained an Overweight rating and slightly raised the price target from $158 to $159 [5] - Stifel analyst Rick Wise maintained a Buy rating and increased the price target from $135 to $145 [5] - Jefferies analyst Matthew Taylor maintained a Hold rating and raised the price target from $135 to $137 [5]